Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 1.00 |
| ▸ | F3 | P13726 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | XDH | P47989 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | P4HB | P07237 | 1/20 | 0.75 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.72 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.72 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.72 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8987383 | 1.00 | MAOB (1.00) | MAOBMAOAF3MAPTXDH | |
| SCHEMBL657702 | 1.00 | MAOB (1.00) | MAOBMAOAF3MAPTXDH | |
| SCHEMBL657701 | 1.00 | MAOB (1.00) | MAOBMAOAF3MAPTXDH | |
| Hydrochloric Acid SCHEMBL11823312 | 0.98 | MAOB (0.97) | MAOBMAOAF3MAPTXDH | |
| Hydrochloric Acid SCHEMBL11823315 | 0.98 | MAOB (0.97) | MAOBMAOAF3MAPTXDH | |
| 4,4'-Dimethoxychalcone SCHEMBL978243 | 0.92 | F3 (1.00) | MAOBMAOAF3MAPTXDH | |
| 4,4'-Dimethoxychalcone SCHEMBL978242 | 0.92 | F3 (1.00) | MAOBMAOAF3MAPTXDH | |
| 4',4-Dichlorochalcone SCHEMBL659211 | 0.87 | MAOB (0.86) | MAOBMAOAF3MAPTCYP1B1 | |
| 4',4-Dichlorochalcone SCHEMBL659210 | 0.87 | MAOB (0.86) | MAOBMAOAF3MAPTCYP1B1 | |
| SCHEMBL25189143 | 0.86 | MAPT (1.00) | MAOBMAOAF3MAPTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| US-9085520-B2 | Composition for treating diabetes and metabolic diseases and a preparation method thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| WO-2013022951-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-02-14 | — | — | WO | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
| US-3931152-A | ANTITUBERCULAR | AMERICAN CYANAMID COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | MAOB 3735/4885MAOA 3153/4885F3 4864/4885 |
| US-20140350304-A1 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF | FABP1, GYS2, CYP7B1 | MAOB 3332/4885MAOA 4277/4885F3 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.